ASP Isotopes Inc. Common Stock (ASPI) 10-Q 14 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 11, 2023
Cover [Abstract]
Entity Registrant Name	ASP Isotopes Inc.
Entity Central Index Key	0001921865
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		37,385,684
Entity File Number	001-41555
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	87-2618235
Entity Address Address Line 1	1101 Pennsylvania Avenue NW
Entity Address Address Line 2	Suite 300
Entity Address City Or Town	Washington
Entity Address State Or Province	DC
Entity Address Postal Zip Code	20004
City Area Code	202
Local Phone Number	756-2245
Security 12b Title	Common Stock, par value $0.01 per share
Trading Symbol	ASPI
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 3,626,165	$ 2,389,140
Prepaid expenses and other current assets	404,365	913,005
Total current assets	4,030,530	3,302,145
Property and equipment, net	7,735,166	8,200,595
Operating lease right-of-use asset	642,422	853,889
Other noncurrent assets	342,680	139,636
Total assets	12,750,798	12,496,265
Current liabilities:
Accounts payable	670,058	1,354,903
Accrued expenses	807,637	361,246
Notes payable	33,854	33,854
Operating lease liability - current	46,565	45,903
Share liability	390,800	140,455
Total current liabilities	1,948,914	1,936,361
Operating lease liability - noncurrent	648,185	742,443
Total liabilities	2,597,099	2,678,804
Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022	0	0
Common stock, $0.01 par value; 500,000,000 shares authorized, 37,385,684 and 35,907,127 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	373,857	359,071
Additional paid-in capital	26,455,828	16,756,426
Accumulated deficit	(15,454,490)	(7,553,066)
Accumulated other comprehensive (loss) income	(1,211,552)	255,030
Total stockholders' equity	10,153,699	9,817,461
Total liabilities and stockholders' equity	$ 12,750,798	$ 12,496,265

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Condensed Consolidated Balance Sheets
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	37,385,684	35,907,127
Common stock, shares outstanding	37,385,684	35,907,127
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 252,880	$ 153,389	$ 460,214	$ 446,440
General and administrative	4,094,664	674,570	7,612,154	1,239,772
Total operating expenses	4,347,544	827,959	8,072,368	1,686,212
Loss from operations	(4,347,544)	(827,959)	(8,072,368)	(1,686,212)
Other income (expense):
Foreign exchange transaction loss	0	0	(935)	0
Change in fair value of share liability	60,100	0	170,385	0
Interest income	1,098	789	1,494	1,454
Total other income	61,198	789	170,944	1,454
Net loss	$ (4,286,346)	$ (827,170)	$ (7,901,424)	$ (1,684,758)
Net loss per share, basic and diluted	$ (0.14)	$ (0.03)	$ (0.27)	$ (0.07)
Weighted average shares of common stock outstanding, basic and diluted	29,796,065	27,109,754	29,535,060	25,798,098
Other comprehensive loss:
Net loss	$ (4,286,346)	$ (827,170)	$ (7,901,424)	$ (1,684,758)
Foreign currency translation	(472,673)	354,528	(1,476,526)	125,271
Total comprehensive loss	$ (4,759,019)	$ (472,642)	$ (9,377,950)	$ (1,559,487)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders Equity (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Balance, shares at Dec. 31, 2021		20,652,500
Balance, amount at Dec. 31, 2021	$ 5,997,664	$ 206,525	$ 8,380,343	$ 18,723	$ (2,607,927)
Issuance of common stock and warrants, net of issuance costs of $285,024, shares		1,187,605
Issuance of common stock and warrants, net of issuance costs of $285,024, amount	2,090,186	$ 11,876	2,078,310	0	0
Issuance of common stock upon exercise of warrants, shares		7,194,847
Issuance of common stock upon exercise of warrants, amount	0	$ 71,948	(71,948)	0	0
Stock-based compensation	20,803	0	20,803	0	0
Foreign currency translation	(229,257)	0	0	(229,257)	0
Net loss	(857,588)	$ 0	0	0	(857,588)
Balance, shares at Mar. 31, 2022		29,034,952
Balance, amount at Mar. 31, 2022	7,021,808	$ 290,349	10,407,508	(210,534)	(3,465,515)
Balance, shares at Dec. 31, 2021		20,652,500
Balance, amount at Dec. 31, 2021	5,997,664	$ 206,525	8,380,343	18,723	(2,607,927)
Settlement of liabilities with related party	0
Balance, shares at Jun. 30, 2022		29,407,127
Balance, amount at Jun. 30, 2022	7,408,537	$ 294,071	11,263,157	143,994	(4,292,685)
Balance, shares at Mar. 31, 2022		29,034,952
Balance, amount at Mar. 31, 2022	7,021,808	$ 290,349	10,407,508	(210,534)	(3,465,515)
Stock-based compensation	210,745	0	210,745	0	0
Foreign currency translation	354,528	0	0	354,528	0
Net loss	(827,170)	$ 0	0	0	(827,170)
Issuance of common stock, net of issuance costs of $95,723, shares		372,175
Issuance of common stock, net of issuance costs of $95,723, amount	648,626	$ 3,722	644,904	0	0
Balance, shares at Jun. 30, 2022		29,407,127
Balance, amount at Jun. 30, 2022	7,408,537	$ 294,071	11,263,157	143,994	(4,292,685)
Balance, shares at Dec. 31, 2022		35,907,127
Balance, amount at Dec. 31, 2022	9,817,461	$ 359,071	16,756,426	255,030	(7,553,066)
Issuance of common stock and warrants, net of issuance costs of $285,024, shares		3,164,557
Stock-based compensation	2,144,099	$ 0	2,144,099	0	0
Foreign currency translation	(1,003,853)	0	0	(1,003,853)	0
Net loss	(3,615,078)	0	0	0	(3,615,078)
Issuance of common stock and warrants, net of issuance costs of $506,390, amount	4,493,610	$ 31,646	4,461,964	0	0
Cancellation of common stock received in exchange for issuance of preferred stock in subsidiary, shares		(3,000,000)
Cancellation of common stock received in exchange for issuance of preferred stock in subsidiary, amount	0	$ (30,000)	30,000	0	0
Issuance of common stock in lieu of commissions, shares		57,250
Issuance of common stock in lieu of commissions, amount	75,570	$ 573	74,997	0	0
Issuance of restricted common stock, shares		1,256,750
Issuance of restricted common stock, amount	0	$ 12,567	(12,567)	0	0
Balance, shares at Mar. 31, 2023		37,385,684
Balance, amount at Mar. 31, 2023	11,911,809	$ 373,857	23,454,919	(748,823)	(11,168,144)
Balance, shares at Dec. 31, 2022		35,907,127
Balance, amount at Dec. 31, 2022	9,817,461	$ 359,071	16,756,426	255,030	(7,553,066)
Settlement of liabilities with related party	626,223
Balance, shares at Jun. 30, 2023		37,385,684
Balance, amount at Jun. 30, 2023	10,153,699	$ 373,857	26,455,828	(1,211,552)	(15,454,490)
Balance, shares at Mar. 31, 2023		37,385,684
Balance, amount at Mar. 31, 2023	11,911,809	$ 373,857	23,454,919	(748,823)	(11,168,144)
Stock-based compensation	2,374,686	0	2,374,686	0	0
Foreign currency translation	(472,673)	0	0	(472,673)	0
Net loss	(4,286,346)	0	0	0	(4,286,346)
Settlement of liabilities with related party	626,223	$ 0	626,223	0	0
Balance, shares at Jun. 30, 2023		37,385,684
Balance, amount at Jun. 30, 2023	$ 10,153,699	$ 373,857	$ 26,455,828	$ (1,211,552)	$ (15,454,490)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from Operating activities
Net loss	$ (7,901,424)	$ (1,684,758)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	167	0
Stock-based compensation	4,518,785	231,548
Fair value of common stock to consultants	496,300	0
Change in fair value of share liability	(170,385)	0
Changes in right-of-use lease asset	32,553	37,476
Changes in operating assets and liabilities:
Deferred offering costs	0	(154,200)
Prepaid expenses and other current assets	294,971	(321,778)
Other noncurrent assets	(48,747)	0
Accounts payable	(351,830)	(35,716)
Accrued expenses	446,564	576,601
Lease liability	(18,844)	(32,722)
Net cash used in operating activities	(2,701,890)	(1,383,549)
Cash flows from investing activities
Purchases of property and equipment	(508,607)	(1,732,595)
Net cash used in investing activities	(508,607)	(1,732,595)
Cash flows from financing Activities
Proceeds from issuance of common stock and warrants	5,000,000	3,119,560
Common stock issuance costs	(506,390)	(255,965)
Repayment of notes payable	0	(13,046)
Net cash provided by financing activities	4,493,610	2,850,549
Net change in cash	1,283,113	(265,595)
Effect of exchange rate changes on cash	(46,088)	125,285
Cash - beginning of period	2,389,140	2,953,721
Cash - end of period	3,626,165	2,813,411
Supplemental disclosures of non-cash investing and financing activities:
Settlement of liabilities with related party	626,223	0
Share liability for non-cash issuance costs	0	124,782
Unpaid financing fees	0	0
Purchase of property and equipment included in accounts payable	318,900	855,404
Settlement of share liability	$ 75,570	$ 0

Organization

Organization	6 Months Ended
	Jun. 30, 2023
Organization
Organization	1. Organization Description of Business ASP Isotopes Inc. was incorporated in the state of Delaware on September 13, 2021, and has its principal operations in Washington, DC. ASP Isotopes Inc.’s subsidiary, ASP Isotopes Holdings Limited (“ASP Guernsey”), has its principal operations in Guernsey. ASP Guernsey’s subsidiary, ASP Isotopes Holdings South Africa Proprietary Limited (“ASP South Africa”), has its principal operations in South Africa. Enlightened Isotopes (Pty) Ltd (“Enlightened Isotopes”), an 80% owned subsidiary of ASP South Africa, was formed in March 2023. ASP Isotopes UK Ltd, a wholly-owned subsidiary of the Company, was incorporated in July 2022. Enriched Energy, LLC, a wholly-owned subsidiary of the Company, was incorporated in January 2022. ASP Isotopes Inc. and its subsidiaries are collectively referred to as “the Company” throughout these consolidated statements. The Company is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the enrichment of natural isotopes into higher concentration products, which could be used in several industries. The Company’s proprietary technology, the Aerodynamic Separation Process (“ASP technology”), originally developed by Klydon Proprietary Ltd (“Klydon”), is designed to enable the production of isotopes. The Company’s initial focus is on the production and commercialization of enriched Carbon-14 (“C-14”), Molybdenum-100 (“Mo-100”) and Silicon-28 (“Si-28”). The Company is working on the completion and commissioning of a first commercial-scale isotope enrichment plant located in South Africa for the enrichment of C-14 and has started planning additional plants. The Company believes the C-14 it may develop using the ASP technology could be used in the development of new pharmaceuticals and agrochemicals. The Company believes that the Mo-100 it may develop using the ASP technology could have significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry. The Company believes the Si-28 it may develop using the ASP technology may be used to develop advanced semiconductors and in quantum computing. The Company also intends to use the ASP technology to produce enriched Uranium-235 (“U-235”). The Company believes that the U-235 it may develop using the ASP technology could be commercialized as a nuclear fuel component for use in the new generation of HALEU-fueled small modular reactors that are now under development for commercial and government uses. In addition, the Company is considering future development of the ASP technology for the separation of Zinc-68, Ytterbium-176, Zinc-67, Nickel-64 and Xenon-136 for potential use in the healthcare target end market, and Chlorine -37 and Lithium-6 for potential use in the nuclear energy target end market. Liquidity and Going Concern Uncertainty The accompanying condensed consolidated financial statements have been prepared on a basis which assumes the Company is a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from any uncertainty related to the Company’s ability to continue as a going concern. Such adjustments could be material. The Company has experienced net losses and negative cash flows from operating activities since its inception. The Company incurred net losses of $7,901,424 and $1,684,758 for the six months ended June 30, 2023 and 2022, respectively. The Company anticipates it will need to continue to raise capital through additional equity and/or debt financings and/or collaborative development agreements to fund its operations. The Company currently expects that its cash of $3,626,165 as of June 30, 2023, will not be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Additional funding will be necessary to complete construction of the first enrichment facility and begin operations, and although the Company has plans to seek additional funding, these plans are not currently probable. There can be no assurance that the Company will achieve or sustain positive cash flows from operations or profitability. The Company is in the process of seeking additional debt and equity financing. However, such funding may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is unable to raise additional capital when required or on acceptable terms, the Company may be required to further scale back or discontinue the advancement of product candidates, further reduce headcount, reorganize, merge with another entity, or cease operations.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies Unaudited Financial Information The Company’s unaudited condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the Company’s opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the year ended December 31, 2022. Basis of Presentation and Use of Estimates The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity instruments and estimating our accrued research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions. Principles of consolidation The Company’s condensed consolidated financial statements include the accounts of ASP Isotopes Inc. and its wholly-owned subsidiaries and, beginning in 2023, the 80% owned Enlightened Isotopes. All intercompany balances and transactions have been eliminated in consolidation. For the three and six months ended June 30, 2023 and 2022, there was no other corporate activity for Enlighted Isotopes other than its formation and therefore there was no non-controlling interest to report on the consolidated balance sheet and no net loss attributable to non-controlling interest on the consolidated statement of operations to report. See Note 9. Currency and currency translation The condensed consolidated financial statements are presented in U.S. dollars, the Company’s reporting currency. The functional currency of ASP Isotopes Inc. and ASP Guernsey is the U.S. dollar. The functional currency of the Company’s subsidiary ASP South Africa is the South African Rand. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities of ASP South Africa are recorded in their South African Rand functional currency and translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue, when recorded, and expenses of ASP South Africa are recorded in their South African Rand functional currency and translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the reporting period. Resulting translation adjustments are recorded separately in stockholders’ equity as a component of accumulated other comprehensive income (loss). The effect of exchange rate changes on intercompany transactions of a long term and permanent nature are credited or charged directly to a separate component of stockholder’s equity. Concentration of Credit Risk and other Risks Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the three and six months ended June 30, 2023 and 2022. Our foreign subsidiaries held cash of approximately $106,000 and $38,000 as of June 30, 2023 and December 31, 2022, respectively, which is included in cash on the consolidated balance sheets. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to indefinitely reinvest our foreign cash outside of the U.S. If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation. Cash The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had no cash equivalents as of June 30, 2023 and December 31, 2022. Segment Information The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The financial information is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources. The Company’s CODM is its chief executive officer. Fair Value of Financial Instruments Accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company’s share liability (Note 9) is now measured as a Level 1 fair value on a recurring basis and was $390,800 as of June 30, 2023. There were no transfers among Level 1, Level 2 or Level 3 categories in the six months ended June 30, 2023. There was a transfer of the share liability from Level 3 to Level 1 as a result of our IPO in the fourth quarter of 2022 as further discussed in Note 9. The following table provides a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 then Level 1 following the IPO in the fourth quarter of 2022): Share Liability Balance, December 31, 2021 116,200 Fair value of additional common stock issuable 174,782 Fair value adjustment (150,527 ) Balance, December 31, 2022 140,455 Less settlement of share liability (75,570 ) Fair value of additional common stock issuable 496,300 Fair value adjustment (170,385 ) Balance, June 30, 2023 $ 390,800 The carrying amounts of accounts payable, accrued expenses and notes payable are considered to be representative of their respective fair values because of the short-term nature of those instruments. Property and Equipment Property and equipment include costs of assets constructed, purchased or leased under a finance lease, related delivery and installation costs and interest incurred on significant capital projects during their construction periods. Expenditures for renewals and betterments also are capitalized, but expenditures for normal repairs and maintenance are expensed as incurred. Costs associated with yearly planned major maintenance are generally deferred and amortized over 12 months or until the same major maintenance activities must be repeated, whichever is shorter. The cost and accumulated depreciation applicable to assets retired or sold are removed from the respective accounts, and gains or losses thereon are included in the statement of operations. We assign the useful lives of our property and equipment based upon our internal engineering estimates, which are reviewed periodically. The estimated useful lives of our property and equipment range from 3 to 5 years, or the shorter of the useful life or remaining life of the lease for leasehold improvements. Depreciation is recorded using the straight-line method. Construction in progress (Note 3) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account, including, but not limited to, leasehold improvements or other such accounts. Leases Leases are accounted for in accordance with ASC 842, which establishes a right-of-use model (“ROU”) that requires a lessee to recognize an ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the reduction of the right-of-use asset. The new standard provides a number of optional practical expedients in transition. The Company has elected to apply (i) the practical expedient, which allows us to not separate lease and non-lease components, for new leases and (ii) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the new standard. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. Impairment of Long-lived Assets Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value would be assessed using a discounted cash flows or other appropriate measures of fair value. The Company did not recognize any impairment losses for the three and six months ended June 30, 2023 or 2022. Research and Development Costs Research and development costs consist primarily of fees paid to consultants and facilities costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. All research and development costs are expensed as incurred. General and Administrative Costs General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, business development, legal, human resources and support functions. Other general and administrative expenses include professional fees for auditing, tax, consulting and patent-related services, rent and utilities and insurance. Stock-based Compensation Stock-based compensation expense represents the cost of the grant date fair value of employee stock awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The Company also awards restricted stock to employees and directors. Restricted stock is generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the restricted stock, which is determined to be the fair market value of the shares of common stock underlying the restricted stock at the date of grant, ratably over the period during which the vesting restrictions lapse. Equity-based compensation expense is classified in the statement of operations in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Prior to the Company’s IPO in November 2022, there was no public market of the Company’s common stock. The fair value of the shares of common stock underlying the Company’s share-based awards was estimated on each grant date by the Company’s board of directors based on then current facts and circumstances. To determine the fair value of the Company’s common stock underlying option grants, the board of directors considered, among other things, input from management and recent third-party financings consummated by the Company. Income Taxes Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. The Company follows the provisions of ASC 740-10, Uncertainty in Income Taxes, The Company has identified the United States, Florida, South Africa and Guernsey as its major tax jurisdictions. Refer to Note 12 for further details. Comprehensive Loss Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss is comprised of net loss and the effect of currency translation adjustments. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires measurements and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments- Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. The ASU 2016-13 guidance became effective as of January 1, 2023, and must be adopted using a modified retrospective approach, with certain exceptions. The adoption of ASU No. 2016-13 during the six months ended June 30, 2023 did not have a material impact on the financial statements. The Company has reviewed recently issued accounting pronouncements and plans to adopt those that are applicable to it. The Company does not expect the adoption of any recently issued pronouncements to have a material impact on its results of operations or financial position.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2023
Property and Equipment
Property and Equipment	3. Property and Equipment Property and equipment consist of the following: June 30, 2023 December 31, 2022 Construction in progress $ 7,728,182 $ 8,200,595 Office equipment 7,151 - Total cost 7,735,333 8,200,595 Accumulated deprecation (167 ) - Net book value $ 7,735,166 $ 8,200,595 The Company is currently building out and qualifying the plant and office space in South Africa. All costs incurred are considered construction in progress because the work is not complete as of June 30, 2023 and December 31, 2022. Depreciation expense for the three and six months ended June 30, 2023 was $167. There was no depreciation expense for the three and six months ended June 30, 2022.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2023
Accrued Expenses
Accrued Expenses	4. Accrued Expenses Accrued expenses consisted of accrued professional fees and employee compensation costs as of June 30, 2023 and December 31, 2022.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2023
Notes Payable
Notes Payable	5. Notes Payable During 2021, the Company executed promissory notes payable with two individuals with an aggregate principal balance of approximately $46,900 (35,000 GBP). The notes were due after a period of two months, followed by mutually agreed upon monthly extensions, and do not bear interest. Subsequent to the issuance of the notes payable, one of the individuals became an officer of the Company. In March 2022, one of the promissory notes totaling $13,046 (10,000 GBP) was repaid in full. As of June 30, 2023 and December 31, 2022, the total promissory notes payable balance was $33,854 and have been automatically extended on a monthly basis.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and contingencies (Note 6)
Commitments and Contingencies	6. Commitments and Contingencies Klydon Proprietary Limited In November 2021, the Company entered into an agreement with Klydon Proprietary Limited (“Klydon”) to design and build a plant to enrich Molybdenum in South Africa. The initial phase of the project includes the building of a plant that can support the production of at least 5kgs of Mo-100, and is expected to be completed in the second half of 2023. The contracted cost for this phase is $6,800,000. The second phase of the project includes the production to be increased to 20kgs of Mo-100 with an additional cost of $6,000,000. The Company can modify the contract scope and overall costs and the contract can be cancelled by either party. As of June 30, 2023 and December 31, 2022, approximately $7,233,000 has been paid under this contract and recorded as construction in progress within property and equipment. Klydon performed a portion of the services required under the Turnkey Contract; however, services were incomplete and many of the services were not completed within the time frame required. As a result, Klydon and ASP South Africa entered into an Acknowledgement of Debt Agreement dated November 30, 2022, whereby Klydon (i) agreed to pledge its assets (the “Pledged Assets”) to ASP South Africa to secure its performance of the Turnkey Contract by December 31, 2022, and (ii) acknowledged that ASP South Africa would suffer damages in the amount of $6,050,000 (“Damage Amount”) should it fail to perform. Under the Acknowledgement of Debt Agreement, the Pledged Assets would serve as collateral for Klydon’s obligation to pay the Damage Amount should Klydon fail to perform. In connection therewith, also on November 30, 2022, ASP South Africa and Klydon entered into a Deed of Security Agreement whereby, if Klydon failed to complete its obligations under the Turnkey Contract by December 31, 2022, all of Klydon’s rights of any nature to and interests of any nature in the Pledged Assets would be transferred to ASP South Africa. Klydon failed to complete its obligations under the Turnkey Contract by December 31, 2022, however, the Company did not perfect its interests in the assets until April 4, 2023. The Company did not believe that the amounts owed by Klydon were realizable, nor did the Company know the timing of any recovery payments. Therefore, a loss recovery receivable was not recorded at any time prior to April 4, 2023. On April 4, 2023, the Company perfected its interest under the Acknowledgement of Debt Agreement, pursuant to which the Company acquired certain intellectual property from Klydon (“Klydon Settlement”). In addition, the Company acquired Klydon's interest in four entities which are inactive and in the process of being dissolved. The Company has concluded that the Klydon Settlement is accounted for under ASC 805, Business Combinations as an asset acquisition since the assets acquired were concentrated in a single identifiable asset from a related party. In conjunction with the Klydon Settlement, the Company recorded an increase to additional paid-in capital for the settlement of all liabilities owed to Klydon at the time of settlement totaling $626,223. Two individuals who are officers and board members of Klydon, one who is now an officer of ASP Isotopes Inc. and the other who is now a scientific advisor of ASP Isotopes Inc., received warrants to purchase common stock of the Company and therefore are considered related parties. See Notes 8 and 9. Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues liabilities for such matters when future expenditures are probable and such expenditures can be reasonably estimated. On October 25, 2022, the Company received a letter from a law firm acting on behalf of Norsk Medisinsk Syklotronsenter AS (“NMS”), asserting, among other things, that the grant of a license to the ASP technology to the Company by Klydon violates a pre-existing exclusive sub-license to the ASP technology granted to Radfarma. The asserted claims, arbitration and/or litigation could include claims against the Company, the Company’s former licensor (Klydon), or Klydon’s present or former sub-licensors alleging infringement of intellectual property rights with respect to the ASP technology on which our company relies. The Company believe these claims have no merit.

Lease

Lease	6 Months Ended
	Jun. 30, 2023
Lease
Lease	7. Lease The Company accounts for leases in accordance with ASC 842 (Note 2). The Company is party to two leases in South Africa. One is an operating lease in Pretoria, South Africa for office and laboratory space. The other is a short term operating lease in Pretoria, South Africa that includes office and laboratory space. The operating lease commenced in October 2021 with the initial term set to expire in December 2030. The Company has applied the guidance in ASC 842 and has determined that it should be classified as an operating lease. The Company’s incremental borrowing rate is approximately 7.5% based on the remaining lease term of the applicable lease. Consequently, a ROU lease asset of approximately $952,521 with a corresponding lease liability of approximately $952,521 based on the present value of the minimum rental payments of such lease was recorded at the inception of the lease. In the consolidated balance sheet as of June 30, 2023, the Company has a ROU asset balance of $642,422 and a current and non-current lease liability of $46,565 and $648,185, respectively, relating to the ROU lease asset. The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company’s lease in South Africa. The short term operating lease commenced in April 2023 with the initial term set to expire in April 2024. The Company has applied the short-term lease practical expedient from the guidance in ASC 842 and will expense the monthly rent as incurred. Quantitative information regarding the Company’s operating lease for the three and six months ended June 30, 2023 and 2022 is as follows: Three Months Ended June 30, Six Months Ended June 30 , 2023 2022 2023 2022 Lease Cost Operating lease cost $ 28,069 $ 34,739 $ 59,229 $ 70,997 Other Information Operating cash flows paid for amounts included in the measurement of lease liabilities $ 21,572 $ 24,836 $ 45,520 $ 50,757 Operating lease liabilities arising from obtaining right-of-use assets $ - $ - $ - $ - Remaining lease term (years) 7.50 8.50 7.75 8.75 Discount rate 7.5 % 7.5 % 7.5 % 7.5 % Future lease payments under noncancelable leases are as follows as of June 30, 2023: Operating Leases Future Lease Payments 2023 (remaining six months) $ 48,546 2024 100,733 2025 108,288 2026 116,409 2027 125,140 Thereafter 434,602 Total lease payments $ 933,718 Less: imputed interest (238,968 ) Total lease liabilities $ 694,750 Less current portion (46,565 ) Lease liability - noncurrent $ 648,185 Lease expense from the short term operating lease for the three and six months ended June, 30, 2023 was $36,530. Future lease payments under the short term operating lease as of June 30, 2023 is $108,721.

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2023
License Agreements
License Agreements	8. License Agreements In September 2021, the Company licensed certain intellectual property from Klydon for the development, production distribution, marketing and sale of Mo-100. The license term is 999 years, unless terminated earlier by either party under certain provisions. Any development efforts improving the intellectual property performed by either Klydon or the Company will be the property of Klydon. There are no upfront, milestone payments, nor royalties on product sales over the term of the license. Two individuals who are officers and board members of Klydon received warrants to purchase common stock of the Company. See Note 9. In January 2022, the Company licensed certain intellectual property from Klydon for the development, production distribution, marketing and sale of uranium isotope U-235 (“U-235”). The license term is 999 years, unless terminated earlier by either party under certain provisions. Any development efforts improving the intellectual property performed by either Klydon or the Company will be the property of Klydon. The Company paid an upfront fee of $100,000, which was expensed to research and development expense. The Company is required to pay a nominal royalty per Kg of product sold plus 10% royalties on product net profits over the term of the contract. One of the officers, who is also a board member of Klydon, became a board member and consultant of ASP Isotopes Inc. and an employee of ASP Guernsey in January 2022. In July 2022, ASP Isotopes UK Ltd (a subsidiary of the Company) entered into a license agreement with Klydon, as licensor, pursuant to which ASP Isotopes UK Ltd acquired from Klydon an exclusive license to use, develop, modify, improve, subcontract and sublicense certain intellectual property rights relating to the ASP technology for the production, distribution, marketing and sale of all isotopes produced using the ASP technology (the “Klydon license agreement”). The Klydon license agreement superseded and replaced the Mo-100 license and U-235 license described in Note 8 above. The Klydon license agreement is royalty-free, has a term of 999 years and is worldwide for the development of the ASP technology and the distribution, marketing and sale of isotopes. Future production of isotopes is limited to member countries of the Nuclear Suppliers Group. In connection with the Klydon license agreement the Company agreed to make an upfront payment of $100,000 (to be included within the payments we make under the Turnkey Contract) and deferred payments of $300,000 over 24 months, which was expensed to research and development expense. Klydon has the right to terminate the exclusivity of the Klydon license agreement in the event that the licensee ceases to carry on activities related to isotope enrichment for a period longer than 24 consecutive months. The $400,000 due to Klydon is in accounts payable as of December 31, 2022. In July 2022, ASP South Africa acquired assets comprising a dormant Silicon-28 aerodynamic separation processing plant from Klydon for ZAR 6,000,000 (which at the then current exchange rate was approximately $354,000), which was recorded to property and equipment, will be payable to Klydon on the later of 180 days of the acquisition and the date on which the assets generate any revenues of any nature. On April 4, 2023, the Company perfected its interest under the Acknowledgement of Debt Agreement (see Note 6), pursuant to which the Company acquired certain intellectual property from Klydon(“Klydon Acquisition”). The Company concluded that the Klydon Acquisition is accounted for under ASC 805, Business Combinations as an asset acquisition since the assets acquired were concentrated in a single identifiable asset from a related party. In conjunction with the Klydon Settlement, the Company recorded an increase to additional paid-in capital for the settlement of all liabilities owed to Klydon at the time of settlement totaling $626,223.

Stockholders Equity

Stockholders Equity	6 Months Ended
	Jun. 30, 2023
Stockholders Equity
Stockholders' Equity	9. Stockholders’ Equity Preferred stock ASP Isotopes Inc. had 10,000,000 shares of preferred stock authorized, of which no shares were issued and outstanding as of June 30, 2023 and December 31, 2022. In conjunction with the formation of Enlightened Isotopes in March 2023, in exchange for 3,000,000 shares of common stock held by an officer and scientific advisor of ASP Isotopes Inc., Enlighted Isotopes issued 2,500 shares of convertible preferred stock. These shares convert into common stock of Enlighted Isotopes at any time upon the election of the preferred stockholders such that these two investors will own 20% of the then outstanding shares on a fully diluted basis. The Company will report the non-controlling interest of future net income or loss on the consolidated balance sheet and statement of operations. Common stock The Company had 500,000,000 shares of common stock authorized, of which 37,385,684 shares were issued and outstanding as of June 30, 2023. Common stockholders are entitled to one vote for each share of outstanding common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends for each share of outstanding common stock, if and when declared by the Board. No dividends have been declared or paid by the Company through June 30, 2023. During 2022, prior to the IPO, the Company issued 1,559,780 shares of common stock at $2.00 per share for gross proceeds of $3,119,560. The Company incurred $255,965 in cash issuance costs and is required to issue 120,491 shares of common stock to the placement agent with an initial fair value of $240,982. In October 2022, the Company amended its agreement with the placement agent for the shares issued from November 2021 through the first nine months of 2022. The shares of common stock issuable to the placement agent was reduced from 120,491 shares to 57,250 shares. The fair value of the 57,250 shares issuable to the placement agent as of December 31, 2022 was $90,455. The fair value of the 57,250 shares issuable to the placement agent just prior to settlement in March 2023 was $75,570, resulting in a change in fair value of share liability of $14,885 for the three months ended March 31, 2023. In March 2023, the Company settled this share liability by issuing 57,250 shares of common stock. In November 2022, the Company was required to issue shares of common stock with a fair value totaling $50,000 to a consultant. As of June 30, 2023, these shares had yet to be issued. In November 2022, the Company completed its IPO, selling an aggregate of 1,250,000 shares of common stock at a price to the public of $4.00 per share, not including 187,500 shares of common stock issuable pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. The Company received net proceeds from the IPO, after deducting underwriting discounts and commissions but before deducting offering costs, of approximately $3.8 million. In February 2023, the Company was required to issue an aggregate of 100,000 shares of common stock to two consultants. The Company determined that the fair value of these two awards was $1.55 and $1.90 per share, respectively, for a total value of $172,500. The fair value of these shares issuable to the two consultants was $56,800 and $85,400 as of June 30, 2023 and March 31, 2023, respectively resulting in a change in fair value of share liability of $28,600 and $115,700 for the three and six months ended June 30, 2023, respectively. As of June 30, 2023, these shares had yet to be issued. In March 2023, the Company was required to issue an aggregate of 100,000 shares of restricted common stock pursuant to a settlement agreement that vests immediately. The Company determined that the fair value of this award was $0.94 per share for a total value of $93,700. The fair value of these shares issuable pursuant to a settlement agreement was $56,800 and $85,400 as of June 30, 2023 and March 31, 2023, respectively, resulting in a change in fair value of share liability of $36,900 and $28,600 for the three and six months ended June 30, 2023, respectively. As of June 30, 2023, these shares had yet to be issued. In March 2023, an officer and scientific advisor of the Company exchanged an aggregate of 3,000,000 shares of ASP Isotopes Inc. common stock for 2,500 shares of Enlighted Isotopes convertible preferred stock. In conjunction with the exchange, Enlighted Isotopes transferred the common shares of ASP Isotopes Inc. to ASP Isotopes and then ASP Isotopes immediately cancelled all 3,000,000 shares. The Company will report the non-controlling interest of future net income or loss on the consolidated balance sheet and statement of operations. In March 2023, the Company’s non-employee board members agreed to receive the 2022 cash director fees totaling $45,000 in shares of common stock. As of June 30, 2023, these shares had yet to be issued. In March 2023, the Company issued 3,164,557 shares of the Company’s common stock at a purchase price of $1.58 per share and warrants to purchase up to an aggregate of 3,164,557 shares of its common stock with an exercise price of $1.75 per share for gross proceeds of $5.0 million. The Company incurred $506,390 in cash issuance costs and issued warrants to purchase up to an aggregate of 221,519 shares of common stock with an exercise price of $1.975 per share to the placement agent with an initial fair value of $179,116. In May 2023, the Company was required to issue an aggregate of 100,000 shares of restricted common stock pursuant to a consultant. The Company determined that the fair value of this award was $0.65 per share for a total value of $65,100. The fair value of these shares issuable to the consultant was $56,800 as of June 30, 2023 resulting in a change in fair value of share liability of $8,300 for the three and six months ended June 30, 2023. As of June 30, 2023, these shares had yet to be issued. In May 2023, the Company was required to issue an aggregate of 300,000 shares of restricted common stock pursuant to an employee. The Company determined that the fair value of this award was $0.55 per share for a total value of $165,000. The fair value of these shares issuable to the employee was $170,400 as of June 30, 2023 resulting in a change in fair value of share liability of $5,400 for the three and six months ended June 30, 2023. As of June 30, 2023, these shares had yet to be issued. Common Stock Warrants The fair values of the warrants issued in the six months ended June 30, 2023 were estimated based on the Black-Scholes model, using the following assumptions: Expected volatility 60.3 % Weighted-average risk-free rate 3.44 % Expected term in years 5.5 Expected dividend yield 0 % In January 2022, warrants to purchase 7,230,822 shares of common stock were net share settled into 7,194,847 shares of common stock per the terms of the underlying warrant agreements. No warrants were exercised in the six months ended June 30, 2023.

Stock Compensation Plan

Stock Compensation Plan	6 Months Ended
	Jun. 30, 2023
Stock Compensation Plan
Stock Compensation Plan	10. Stock Compensation Plan Equity Incentive Plan In October 2021, the Company adopted the 2021 Stock Incentive Plan (“2021 Plan”) that provided for the issuance of common stock to employees, nonemployee directors, and consultants. Recipients of incentive stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2021 Plan provided for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2021 Plan is ten years. The maximum number of shares initially available for issuance under the 2021 Plan was 6,000,000. No further options are available to be issued under the 2021 Plan. In November 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”) that provides for the issuance of common stock to employees, nonemployee directors, and consultants. Recipients of incentive stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2022 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2022 Plan is ten years. The number of shares of the Company’s common stock initially reserved for issuance under the 2022 Plan is equal to 5,000,000, subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2023 and continuing until, and including, the fiscal year ending December 31, 2033, equal to the lesser of 5% of the number of shares of the Company’s common stock outstanding on such date or an amount determined by the Company’s board of directors. As of June 30, 2023, 988,606 shares remain available for future grant under the Plan. Stock Options The following table sets forth the activity for the Company’s stock options during the periods presented: Number of Options Weighted- Average Exercise Price per Share Weighted Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value Outstanding as of December 31, 2022 2,901,000 $ 1.91 9.4 $ 199,500 Granted - $ - Forfeited (50,000 ) $ 0.25 Outstanding as of June 30, 2023 2,851,000 $ 1.91 8.9 $ 47,700 Exercisable as of June 30, 2023 1,285,025 $ 1.89 8.8 $ 26,500 Vested or expected to vest as of June 30, 2023 2,851,000 $ 1.91 8.9 $ 47,700 For the six months ended June 30, 2023, no options were granted. For the six months ended June 30, 2022, the Company granted 2,116,000 options with an exercise price of $2.00 per share that vest monthly over one to three years. The weighted-average grant date fair value of options granted for the six months ended June 30, 2022 was $1.17. The Company recorded stock compensation from options of $209,774 and $189,980 for the three months ended June 30, 2023 and 2022, respectively. The Company recorded stock compensation from options of $565,985 and $198,283 for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, there was $1,736,708 of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan, which is expected to be recognized over a weighted average period of approximately 1.7 years. Stock Awards In October 2021, the Company issued 1,500,000 shares of restricted common stock to its Chief Executive Officer. The number of shares that vest is dependent on achieving certain performance conditions and dependent market conditions upon the third anniversary from the date of grant. The Company determined that the fair value of this award was $0.25 per share for a total value of $375,000. Upon reaching the performance condition, the Company will recognize stock compensation expense over the remaining measurement period. No stock compensation was recorded for this award for the three and six months ended June 30, 2023 and 2022. In October 2021, the Company issued 600,000 shares of restricted common stock to a consultant who is also a member of the board of directors, that vest annually over three years. The Company determined that the fair value of this award was $0.25 per share for a total value of $150,000. The consulting agreement also included future awards of common stock for continued service, however in March 2023, the consulting agreement was amended and these future awards were cancelled. In July 2022, the Company issued 600,000 shares of restricted common stock to a consultant who is also a member the of board of directors, that vest quarterly over one year. The Company determined that the fair value of this award was $2.00 per share for a total value of $1,200,000. In July 2022, the Company issued 100,000 shares of restricted common stock to a consultant, that vests on the one-year anniversary of the grant. The Company determined that the fair value of this award was $2.00 per share for a total value of $200,000. In November 2022, the Company issued 3,000,000 shares of restricted common stock to certain employees and directors, that vest two to four years from the date of the grant. The Company determined that the fair value of these awards was $2.63 per share for a total value of $7,890,000. In December 2022, the Company issued an aggregate of 1,550,000 shares of restricted common stock to its Chief Executive Officer and Chairman, Interim Chief Financial Officer and a director that vest quarterly over one year from the date of the grant. The Company determined that the fair value of these awards was $1.58 per share for a total value of $2,449,000. In March 2023, the Company issued an aggregate of 1,256,750 shares of restricted common stock to its Chief Executive Officer and Chairman and a director that vests quarterly over one year from the date of the grant. The Company determined that the fair value of these awards was $1.80 per share for a total value of $2,262,150. The Company recorded stock compensation from stock awards totaling $2,164,913 and $12,500 for the three months ended June 30, 2023 and 2022, respectively. The Company recorded stock compensation from stock awards totaling $3,952,800 and $25,000 for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, there is $11,279,197 of unrecognized compensation cost related to the non-vested portion of stock awards that is expected to be recognized over the next 1.7 years. The following table summarizes vesting of restricted common stock: Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested as of December 31, 2022 7,000,000 $ 1.75 Granted 1,256,750 $ 1.80 Vested (1,389,188 ) $ 1.72 Unvested as of June 30, 2023 6,867,562 $ 1.66 Stock-based Compensation Expense Stock-based compensation expense for all stock awards recognized in the accompanying consolidated statements of operations is as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 General and administrative $ 2,281,277 $ 187,057 $ 4,332,985 $ 207,860 Research and development 93,409 23,688 185,800 23,688 Total $ 2,374,686 $ 210,745 $ 4,518,785 $ 231,548

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Net Loss Per Share
Net Loss Per Share	11. Net Loss Per Share The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented. The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss $ (4,286,346 ) $ (827,170 ) $ (7,901,424 ) $ (1,684,758 ) Denominator: Weighted average common stock outstanding, basic and diluted 29,796,065 27,109,754 29,535,060 25,798,098 Net loss per share, basic and diluted $ (0.14 ) $ (0.03 ) $ (0.27 ) $ (0.07 ) The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive: As of June 30, 2023 2022 Options to purchase common stock 2,851,000 2,266,000 Warrants to purchase common stock 3,386,076 - Restricted stock 6,867,562 2,100,000 Total shares of common stock equivalents 13,104,638 4,366,000

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Taxes
Income Taxes	12. Income Taxes The Company has no income tax expense due to operating losses incurred for the three and six months ended June 30, 2023 and 2022. The Company has provided a full valuation allowance on the net deferred tax asset because management has determined that it is more-likely-than-not that the Company will not earn income sufficient to realize the deferred tax assets during a future period. The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition threshold to be recognized. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the Company’s balance sheets and has not recognized interest and/or penalties in the statements of operations and comprehensive loss for the three and six months ended June 30, 2023. Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustments may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue. As of June 30, 2023 and December 31, 2022, there were no uncertain tax positions. As of June 30, 2023, the Company did not recognize any interest and penalties associated with unrecognized tax benefits. Due to net operating losses incurred, tax years from inception remain open to examination by the Federal and State taxing jurisdictions to which we are subject. The Company is not currently under Internal Revenue Services (IRS), state or local tax examination. Ownership changes, as defined in the IRC, may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income pursuant to IRC Section 382 or similar provisions. Subsequent ownership changes could further affect the limitation in future years. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company’s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company’s ability to utilize net operating loss and research and development credit carryforwards in the future.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events
Subsequent Events	13. Subsequent Events The Company has evaluated subsequent events through August 14, 2023, the date on which the accompanying financial statements were issued and none were noted.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Unaudited Financial Information	The Company’s unaudited condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the Company’s opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the year ended December 31, 2022.
Basis of Presentation and Use of Estimates	The Company’s condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity instruments and estimating our accrued research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
Principles of consolidation	The Company’s condensed consolidated financial statements include the accounts of ASP Isotopes Inc. and its wholly-owned subsidiaries and, beginning in 2023, the 80% owned Enlightened Isotopes. All intercompany balances and transactions have been eliminated in consolidation. For the three and six months ended June 30, 2023 and 2022, there was no other corporate activity for Enlighted Isotopes other than its formation and therefore there was no non-controlling interest to report on the consolidated balance sheet and no net loss attributable to non-controlling interest on the consolidated statement of operations to report. See Note 9.
Currency and currency translation	The condensed consolidated financial statements are presented in U.S. dollars, the Company’s reporting currency. The functional currency of ASP Isotopes Inc. and ASP Guernsey is the U.S. dollar. The functional currency of the Company’s subsidiary ASP South Africa is the South African Rand. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the consolidated statements of operations. Assets and liabilities of ASP South Africa are recorded in their South African Rand functional currency and translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue, when recorded, and expenses of ASP South Africa are recorded in their South African Rand functional currency and translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the reporting period. Resulting translation adjustments are recorded separately in stockholders’ equity as a component of accumulated other comprehensive income (loss). The effect of exchange rate changes on intercompany transactions of a long term and permanent nature are credited or charged directly to a separate component of stockholder’s equity.
Concentration of Credit Risk and other Risks	Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business, will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the three and six months ended June 30, 2023 and 2022. Our foreign subsidiaries held cash of approximately $106,000 and $38,000 as of June 30, 2023 and December 31, 2022, respectively, which is included in cash on the consolidated balance sheets. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to indefinitely reinvest our foreign cash outside of the U.S. If we were to repatriate foreign cash to the U.S., we would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.
Cash	The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had no cash equivalents as of June 30, 2023 and December 31, 2022.
Segment Information	The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The financial information is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources. The Company’s CODM is its chief executive officer.
Fair Value of Financial Instruments	Accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company’s share liability (Note 9) is now measured as a Level 1 fair value on a recurring basis and was $390,800 as of June 30, 2023. There were no transfers among Level 1, Level 2 or Level 3 categories in the six months ended June 30, 2023. There was a transfer of the share liability from Level 3 to Level 1 as a result of our IPO in the fourth quarter of 2022 as further discussed in Note 9. The following table provides a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 then Level 1 following the IPO in the fourth quarter of 2022): Share Liability Balance, December 31, 2021 116,200 Fair value of additional common stock issuable 174,782 Fair value adjustment (150,527 ) Balance, December 31, 2022 140,455 Less settlement of share liability (75,570 ) Fair value of additional common stock issuable 496,300 Fair value adjustment (170,385 ) Balance, June 30, 2023 $ 390,800 The carrying amounts of accounts payable, accrued expenses and notes payable are considered to be representative of their respective fair values because of the short-term nature of those instruments.
Property and Equipment	Property and equipment include costs of assets constructed, purchased or leased under a finance lease, related delivery and installation costs and interest incurred on significant capital projects during their construction periods. Expenditures for renewals and betterments also are capitalized, but expenditures for normal repairs and maintenance are expensed as incurred. Costs associated with yearly planned major maintenance are generally deferred and amortized over 12 months or until the same major maintenance activities must be repeated, whichever is shorter. The cost and accumulated depreciation applicable to assets retired or sold are removed from the respective accounts, and gains or losses thereon are included in the statement of operations. We assign the useful lives of our property and equipment based upon our internal engineering estimates, which are reviewed periodically. The estimated useful lives of our property and equipment range from 3 to 5 years, or the shorter of the useful life or remaining life of the lease for leasehold improvements. Depreciation is recorded using the straight-line method. Construction in progress (Note 3) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account, including, but not limited to, leasehold improvements or other such accounts.
Leases	Leases are accounted for in accordance with ASC 842, which establishes a right-of-use model (“ROU”) that requires a lessee to recognize an ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the reduction of the right-of-use asset. The new standard provides a number of optional practical expedients in transition. The Company has elected to apply (i) the practical expedient, which allows us to not separate lease and non-lease components, for new leases and (ii) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the new standard. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.
Impairment of Long-lived Assets	Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value would be assessed using a discounted cash flows or other appropriate measures of fair value. The Company did not recognize any impairment losses for the three and six months ended June 30, 2023 or 2022.
Research and Development Costs	Research and development costs consist primarily of fees paid to consultants and facilities costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. All research and development costs are expensed as incurred.
General and Administrative Costs	General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, business development, legal, human resources and support functions. Other general and administrative expenses include professional fees for auditing, tax, consulting and patent-related services, rent and utilities and insurance.
Stock-based Compensation	Stock-based compensation expense represents the cost of the grant date fair value of employee stock awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The Company also awards restricted stock to employees and directors. Restricted stock is generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the restricted stock, which is determined to be the fair market value of the shares of common stock underlying the restricted stock at the date of grant, ratably over the period during which the vesting restrictions lapse. Equity-based compensation expense is classified in the statement of operations in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Prior to the Company’s IPO in November 2022, there was no public market of the Company’s common stock. The fair value of the shares of common stock underlying the Company’s share-based awards was estimated on each grant date by the Company’s board of directors based on then current facts and circumstances. To determine the fair value of the Company’s common stock underlying option grants, the board of directors considered, among other things, input from management and recent third-party financings consummated by the Company.
Income Taxes	Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. The Company follows the provisions of ASC 740-10, Uncertainty in Income Taxes, The Company has identified the United States, Florida, South Africa and Guernsey as its major tax jurisdictions. Refer to Note 12 for further details.
Comprehensive Loss	Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss is comprised of net loss and the effect of currency translation adjustments.
Recently Issued Accounting Pronouncements	In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires measurements and recognition of expected credit losses for financial assets. In April 2019, the FASB issued clarification to ASU 2016-13 within ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments- Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. The ASU 2016-13 guidance became effective as of January 1, 2023, and must be adopted using a modified retrospective approach, with certain exceptions. The adoption of ASU No. 2016-13 during the six months ended June 30, 2023 did not have a material impact on the financial statements. The Company has reviewed recently issued accounting pronouncements and plans to adopt those that are applicable to it. The Company does not expect the adoption of any recently issued pronouncements to have a material impact on its results of operations or financial position.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Basis of Presentation and Summary of Significant Accounting Policies
Schedule of liabilities measured at fair value on a recurring basis	Share Liability Balance, December 31, 2021 116,200 Fair value of additional common stock issuable 174,782 Fair value adjustment (150,527 ) Balance, December 31, 2022 140,455 Less settlement of share liability (75,570 ) Fair value of additional common stock issuable 496,300 Fair value adjustment (170,385 ) Balance, June 30, 2023 $ 390,800

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property and Equipment
Schedule of property and Equipment	June 30, 2023 December 31, 2022 Construction in progress $ 7,728,182 $ 8,200,595 Office equipment 7,151 - Total cost 7,735,333 8,200,595 Accumulated deprecation (167 ) - Net book value $ 7,735,166 $ 8,200,595

Lease (Tables)

Lease (Tables)	6 Months Ended
	Jun. 30, 2023
Lease
Schedule of quantitative information regarding operating lease	Three Months Ended June 30, Six Months Ended June 30 , 2023 2022 2023 2022 Lease Cost Operating lease cost $ 28,069 $ 34,739 $ 59,229 $ 70,997 Other Information Operating cash flows paid for amounts included in the measurement of lease liabilities $ 21,572 $ 24,836 $ 45,520 $ 50,757 Operating lease liabilities arising from obtaining right-of-use assets $ - $ - $ - $ - Remaining lease term (years) 7.50 8.50 7.75 8.75 Discount rate 7.5 % 7.5 % 7.5 % 7.5 %
Schedule of future lease payments under noncancelable leases	Operating Leases Future Lease Payments 2023 (remaining six months) $ 48,546 2024 100,733 2025 108,288 2026 116,409 2027 125,140 Thereafter 434,602 Total lease payments $ 933,718 Less: imputed interest (238,968 ) Total lease liabilities $ 694,750 Less current portion (46,565 ) Lease liability - noncurrent $ 648,185

Stockholders Equity (Tables)

Stockholders Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Stockholders Equity
Schedule of fair values of the warrants	Expected volatility 60.3 % Weighted-average risk-free rate 3.44 % Expected term in years 5.5 Expected dividend yield 0 %

Stock Compensation Plan (Tables

Stock Compensation Plan (Tables)	6 Months Ended
	Jun. 30, 2023
Stock Compensation Plan
Schedule of company's stock options	Number of Options Weighted- Average Exercise Price per Share Weighted Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value Outstanding as of December 31, 2022 2,901,000 $ 1.91 9.4 $ 199,500 Granted - $ - Forfeited (50,000 ) $ 0.25 Outstanding as of June 30, 2023 2,851,000 $ 1.91 8.9 $ 47,700 Exercisable as of June 30, 2023 1,285,025 $ 1.89 8.8 $ 26,500 Vested or expected to vest as of June 30, 2023 2,851,000 $ 1.91 8.9 $ 47,700
Schedule of summarizes vesting of restricted common stock	Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested as of December 31, 2022 7,000,000 $ 1.75 Granted 1,256,750 $ 1.80 Vested (1,389,188 ) $ 1.72 Unvested as of June 30, 2023 6,867,562 $ 1.66
Schedule of stock-based compensation expense	Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 General and administrative $ 2,281,277 $ 187,057 $ 4,332,985 $ 207,860 Research and development 93,409 23,688 185,800 23,688 Total $ 2,374,686 $ 210,745 $ 4,518,785 $ 231,548

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Net Loss Per Share
Schedule of basic and diluted net loss per share	Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss $ (4,286,346 ) $ (827,170 ) $ (7,901,424 ) $ (1,684,758 ) Denominator: Weighted average common stock outstanding, basic and diluted 29,796,065 27,109,754 29,535,060 25,798,098 Net loss per share, basic and diluted $ (0.14 ) $ (0.03 ) $ (0.27 ) $ (0.07 )
Schedule of diluted net loss per share because to include them would be anti-dilutive	As of June 30, 2023 2022 Options to purchase common stock 2,851,000 2,266,000 Warrants to purchase common stock 3,386,076 - Restricted stock 6,867,562 2,100,000 Total shares of common stock equivalents 13,104,638 4,366,000

Organization (Details Narrative

Organization (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Organization
Net loss	$ (4,286,346)	$ (827,170)	$ (7,901,424)	$ (1,684,758)
Cash	$ 3,626,165		$ 3,626,165

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Basis of Presentation and Summary of Significant Accounting Policies
Fair value, opening balance	$ 140,455	$ 116,200
Less settlement of share liability	(75,570)
Fair value of additional common stock issuable	496,300	174,782
Fair value adjustment	(170,385)	(150,527)
Fair value, ending balance	$ 390,800	$ 140,455

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Federal deposit insurance limit	$ 250,000
Cash held by subsidiaries	106,000	$ 38,000
Fair value liability	$ 390,800
Minimum [Member] | Property and equipment [Member]
Estimated useful lives	3 years
Maximum [Member] | Property and equipment [Member]
Estimated useful lives	5 years

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Total cost	$ 7,735,333	$ 8,200,595
Accumulated deprecation	(167)	0
Net book value	7,735,166	8,200,595
Construction In Progress
Total cost	7,728,182	8,200,595
Office Equipment
Total cost	$ 7,151	$ 0

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property and Equipment
Depreciation expense	$ 167	$ 0	$ 167	$ 0

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Mar. 31, 2022
Total promissory notes payable balance	$ 33,854	$ 33,854
Promissory Note [Member]
Notes payable			$ 13,046
Total promissory notes payable balance	$ 46,900

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)		6 Months Ended
	Apr. 04, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Contracted cost		$ 6,800,000
Damage amount		6,050,000
Property and equipment payment			$ 7,233,000	$ 7,233,000
Loss recovery receivable	$ 626,223
Second Phase [Member]
Contracted cost		$ 6,000,000

Lease (Details)

Lease (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Lease
Operating lease cost	$ 28,069	$ 34,739	$ 59,229	$ 70,997
Other Information
Operating cash flows paid for amounts included in the measurement of lease liabilities	21,572	24,836	45,520	50,757
Operating lease liabilities arising from obtaining right-of-use assets	$ 0	$ 0	$ 0	$ 0
Remaining lease term (years)	7 years 6 months	8 years 6 months	9 months	8 years 9 months
Discount rate	7.50%	7.50%	7.50%	7.50%

Lease (Details 1)

Lease (Details 1) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Oct. 31, 2021
Lease
2023	$ 48,546
2024	100,733
2025	108,288
2026	116,409
2027	125,140
Thereafter	434,602
Total lease payments	933,718
Less: imputed interest	(238,968)
Total lease liabilities	694,750		$ 952,521
Less current portion	(46,565)
Lease liability - noncurrent	$ 648,185	$ 742,443

Lease (Details Narrative)

Lease (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Oct. 31, 2021	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Lease
Incremental borrowing rate	7.50%
ROU lease asset	$ 952,521	$ 642,422	$ 642,422	$ 853,889
Operating lease liability	$ 952,521	694,750	694,750
Operating lease liability current		46,565	46,565
Short term operating lease		36,530	36,530
Operating lease liability - noncurrent		648,185	648,185
Future lease payments under short term operating lease		$ 108,721	$ 108,721

License Agreements (Details Nar

License Agreements (Details Narrative) - USD ($)		1 Months Ended			6 Months Ended
	Apr. 04, 2023	Dec. 31, 2022	Jul. 31, 2022	Jan. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Accounts payable		$ 400,000			$ (351,830)	$ (35,716)
Gain on settlement for all liabilities	$ 626,223
Research and development expense				$ 100,000
Royalties percentage				10%
Acquired assets			$ 6,000,000		$ 508,607	$ 1,732,595
Turnkey Contract [Member]
Research and development expense			100,000
Deferred payment			300,000
Acquired assets			$ 354,000

Stockholders Equity (Details)

Stockholders Equity (Details)	6 Months Ended
	Jun. 30, 2023
Stockholders Equity
Expected volatility	60.30%
Weighted-average risk-free rate	3.44%
Expected term in years	5 years 6 months
Expected dividend yield	0%

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended			6 Months Ended		12 Months Ended
	May 31, 2023	Nov. 30, 2022	Jan. 31, 2022	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Preferred stock authorized				10,000,000			10,000,000		10,000,000
Common stock shares authorized				500,000,000			500,000,000		500,000,000
Common stock shares issued				37,385,684			37,385,684		35,907,127
Common stock shares outstanding				37,385,684			37,385,684		35,907,127
Issuance of common stock							172,500		1,559,780
Issuance of common stock, value		$ 3,800,000			$ 5,000,000		$ 5,000,000	$ 3,119,560	$ 3,119,560
Common stock price per share		$ 4
Issuance of cost					$ 506,390		506,390	255,965	$ 255,965
Issuance of share									120,491
Fair value of share issue									$ 240,982
Fair value of share issue				$ 390,800			390,800		140,455
Change in fair value of share liability				$ 60,100		$ 0	$ 170,385	$ 0
Issuance of shares		1,250,000
Cancellation of common stock received in exchange for issuance of convertible preferred stock in subsidiary, shares					3,000,000
Exchange of common shares into Convertible preferred stock							3,000,000
Convertible preferred stock				2,500			2,500
Cash director fees							$ 45,000
Fair value of share issuable				56,800	85,400		56,800
Exercise price per share					$ 1.75
Warrants purchased					3,164,557
Private Placement [Member]
Fair value of share issue									$ 90,455
Common stock issuable									57,250
Change in fair value of share liability					$ 14,885
Exercise price per share					$ 1.975
Aggregate common stock					221,519
Initial fair value					$ 179,116
Settlement of share liability by issuing share					75,570		57,250
Private Placement [Member] | Minimum [Member]
Common stock issuable									120,491
Private Placement [Member] | Maximum [Member]
Common stock issuable					57,250
Common Stock Warrants [Member]
Issuance of common stock			7,230,822
Common stock shares of warrant agreements			7,194,847
Common Stocks
Issuance of share					3,164,557
Purchase price of share					$ 1.58
Consultant [Member]
Issuance of common stock		50,000
Two Consultant [Member]
Issuance of common stock					3,000,000
Fair value of share issue					$ 2,500
Change in fair value of share liability				$ 28,600			$ 115,700
Fair value of share issuable				56,800	85,400		56,800
Two Consultant [Member] | Minimum [Member]
Fair value of per share				$ 1.55			$ 1.55
Two Consultant [Member] | Maximum [Member]
Fair value of per share				$ 1.90			$ 1.90
Restricted common stock [Member]
Issuance of common stock					100,000		100,000
Issuance of common stock, value					$ 93,700
Change in fair value of share liability				$ 36,900			$ 28,600
Fair value of per share					$ 0.94
Restricted common stock One [Member]
Issuance of common stock	100,000
Issuance of common stock, value	$ 65,100
Change in fair value of share liability				$ 56,800			$ 8,300
Fair value of per share	$ 0.65			$ 0.65			$ 0.65
Restricted common stock Two [Member]
Issuance of common stock							300,000
Issuance of common stock, value							$ 165,000
Change in fair value of share liability				$ 170,400			$ 5,400
Fair value of per share				$ 0.55			$ 0.55

Stock Compensation Plan (Detail

Stock Compensation Plan (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Stock Compensation Plan
Number of option outstanding, beginning	2,901,000
Number of Options, Granted	0	2,116,000
Number of options, Forfeited	$ (50,000)
Number of option outstanding, ending	2,851,000
Number of option exercisable	1,285,025
Number of option vested or expected to vest	2,851,000	2,266,000
Weighted- Average Exercise Price per Share outstanding, beginning	$ 1.91
Weighted- Average Exercise Price per Share, Granted	0	$ 2
Weighted- Average Exercise Price per Share, Forfeited	0.25
Weighted- Average Exercise Price per Share outstanding, ending	1.91
Weighted- Average Exercise Price per Share outstanding, Exercisable	1.89
Weighted- Average Exercise Price per Share outstanding, Vested or expected to vest	$ 1.91
Weighted Average Remaining Contractual Term (in Years), beginning	9 years 4 months 24 days
Weighted Average Remaining Contractual Term (in Years),ending	8 years 10 months 24 days
Weighted Average Remaining Contractual Term (in Years), Exercisable	8 years 9 months 18 days
Weighted Average Remaining Contractual Term (in Years), Vested or expected to vest	8 years 10 months 24 days
Aggregate instrict value outstanding, beginning	$ 199,500
Aggregate instrict value outstanding, ending	47,700
Aggregate instrict value outstanding, Exercisable	26,500
Aggregate instrict value outstanding, Vested or expected to vest	$ 47,700

Stock Compensation Plan (Deta_2

Stock Compensation Plan (Details 1)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Stock Compensation Plan
Number of Shares, Unvested at Beginning Balance | shares	7,000,000
Number of Shares, Granted | shares	1,256,750
Number of Shares, Vested | shares	(1,389,188)
Number of Shares, Unvested at Ending Balance | shares	6,867,562
Weighted Average Grant Date Fair Value Per Share, Unvested at Beginning Balance | $ / shares	$ 1.75
Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares	1.80
Weighted Average Grant Date Fair Value Per Share, Vested | $ / shares	1.72
Weighted Average Grant Date Fair Value Per Share, Unvested at Ending Balance | $ / shares	$ 1.66

Stock Compensation Plan (Deta_3

Stock Compensation Plan (Details 2) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock based compensation expense	$ 2,374,686	$ 210,745	$ 4,518,785	$ 231,548
General and administrative [Member]
Stock based compensation expense	2,281,277	187,057	4,332,985	207,860
Research and development [Member]
Stock based compensation expense	$ 93,409	$ 23,688	$ 185,800	$ 23,688

Stock Compensation Plan (Deta_4

Stock Compensation Plan (Details Narrative) - USD ($)	1 Months Ended					3 Months Ended		6 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Nov. 30, 2022	Jul. 31, 2022	Oct. 31, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Number of shares issued		5,000,000				6,000,000		6,000,000
Number of Options, Granted								0	2,116,000
Weighted- Average Exercise Price per Share, Granted								$ 0	$ 2
Stock compensation						$ 2,374,686	$ 210,745	$ 4,518,785	$ 231,548
Weighted-average grant date fair value of options granted									$ 1.17
Stock Awards [Member]
Stock option granted			3,000,000	100,000
Weighted average fair value			$ 2.63	$ 2
Stock compensation						2,164,913	12,500	3,952,800	$ 25,000
Unrecognized compensation cost						11,279,197		$ 11,279,197
Weighted average period term								1 year 8 months 12 days
Total value			$ 7,890,000	$ 200,000
Stock Options [Member]
Stock compensation						209,774	$ 189,980	$ 565,985	$ 198,283
Unrecognized compensation cost						$ 1,736,708		$ 1,736,708
Weighted average period term								1 year 8 months 12 days
Chief Executive Officer [Member] | Stock Awards [Member]
Stock option granted	1,256,750	1,550,000			1,500,000
Weighted average fair value	$ 1.80	$ 1.58			$ 0.25
Total value	$ 2,262,150	$ 2,449,000			$ 375,000
Board of Directors [Member] | Stock Awards [Member]
Stock option granted				600,000	600,000
Weighted average fair value				$ 2	$ 0.25
Total value				$ 1,200,000	$ 150,000
Equity Incentive Plan [Member]
Shares available for future grant						988,606		988,606

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss	$ (4,286,346)	$ (827,170)	$ (7,901,424)	$ (1,684,758)
Denominator:
Weighted average common stock outstanding, basic and diluted	29,796,065	27,109,754	29,535,060	25,798,098
Net loss per share, basic and diluted	$ (0.14)	$ (0.03)	$ (0.27)	$ (0.07)

Net Loss Per Share (Details 1)

Net Loss Per Share (Details 1) - shares	Jun. 30, 2023	Jun. 30, 2022
Net Loss Per Share
Options to purchase common stock	2,851,000	2,266,000
Warrants to purchase Common Stock	3,386,076	0
Restricted stock	6,867,562	2,100,000
Total shares of common stock equivalents	13,104,638	4,366,000